Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherAssets,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,totalCashflowsFromInvestingActivities,netBorrowings,repurchaseOfStock,capitalExpenditures,investments,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,exchange,exchangeDataDelayedBy,marketState,twoHundredDayAverageChangePercent,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,regularMarketChangePercent,regularMarketDayRange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,ESPR,-304366000.0,28192100,,,-43668000,,-43668000,46318000,13785000,-32533000,-32533000,,-11144000,,,,0,40659000,73192000,26874000,-11135000,,-43668000,-43668000,56000.0,722534000.0,584771000.0,-304310000.0,3930000.0,280461000.0,26000.0,-971872000.0,2347000.0,-54998000.0,219186000.0,82644000.0,12469000.0,5231000.0,275174000.0,21854000.0,497860000.0,23714000.0,29353000.0,,1845000.0,49113000.0,-9974000.0,168000.0,1247000.0,-47866000.0,153000.0,-3684000.0,-9466000.0,48945000.0,16524000.0,,,,,,192530000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,13.02,13.04,13.05,10,8,finmb_28236,NasdaqGM,"Esperion Therapeutics, Inc.",USD,573709,539883,0.21990013,0.017126178,12.84 - 40.2,-27.1401,-0.67512685,12.84,40.2,1620144060,1635764340,1636113600,-5.767,-5.23,-10.48,-1.2461737,-10.289,15.111667,-2.0517664,-0.13577367,22.679565,-9.619665,368186016,-2.4971128,-1.2693071,15,America/New_York,EDT,-14400000,False,False,NGM,0,REGULAR,-0.42415562,"Esperion Therapeutics, Inc.",13.0599,1630510370,0.039899826,13.16,13.21,12.885,98168,us_market,2,0.30645028,12.885 - 13.21,1.1,,,40.2,12.84,15.11,22.68,573.71k,539.88k,28.19M,,26.26M,1.58%,108.45%,9.02M,14.35,49.77%,34.33%,9.03M,,,,,,0.00%,,,1:6,"Jun 10, 2013","Dec 30, 2020","Jun 29, 2021",0.00%,-447.89%,-56.93%,,62.11M,2.32,-80.80%,78.22M,-277.55M,-324.52M,-5.77,,219.19M,7.75,514.6M,,3.33,-10.29,-292.16M,-215.61M,Value,48108,Healthcare,479,8,7,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",Ann Arbor,734 887 3903,MI,8,1609372800,1625097600,7,United States,http://www.esperion.com,86400,8,3891 Ranchero Drive,Biotechnology,Suite 150
t-1,ESPR,-269450000.0,28192100,27954000.0,,-90935000,,-90935000,47764000,-21760000,-69524000,-69524000,,-8125000,,,,0,7978000,77502000,29738000,-21411000,,-90935000,-90935000,56000.0,713782000.0,548000000.0,-269394000.0,20793000.0,278606000.0,26000.0,-928204000.0,1290000.0,-54998000.0,217939000.0,97893000.0,6353000.0,5975000.0,272575000.0,22255000.0,446297000.0,27633000.0,30342000.0,,-20702000.0,2045000.0,15234000.0,2668000.0,-87023000.0,-89068000.0,153000.0,-3894000.0,-9466000.0,-623000.0,10676000.0,,,,,,174682000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,13.02,13.04,13.05,10,8,finmb_28236,NasdaqGM,"Esperion Therapeutics, Inc.",USD,573709,539883,0.21990013,0.017126178,12.84 - 40.2,-27.1401,-0.67512685,12.84,40.2,1620144060,1635764340,1636113600,-5.767,-5.23,-10.48,-1.2461737,-10.289,15.111667,-2.0517664,-0.13577367,22.679565,-9.619665,368186016,-2.4971128,-1.2693071,15,America/New_York,EDT,-14400000,False,False,NGM,0,REGULAR,-0.42415562,"Esperion Therapeutics, Inc.",13.0599,1630510370,0.039899826,13.16,13.21,12.885,98168,us_market,2,0.30645028,12.885 - 13.21,1.1,,,40.2,12.84,15.11,22.68,573.71k,539.88k,28.19M,,26.26M,1.58%,108.45%,9.02M,14.35,49.77%,34.33%,9.03M,,,,,,0.00%,,,1:6,"Jun 10, 2013","Dec 30, 2020","Jun 29, 2021",0.00%,-447.89%,-56.93%,,62.11M,2.32,-80.80%,78.22M,-277.55M,-324.52M,-5.77,,219.19M,7.75,514.6M,,3.33,-10.29,-292.16M,-215.61M,Value,48108,Healthcare,479,8,7,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",Ann Arbor,734 887 3903,MI,8,1609372800,1625097600,7,United States,http://www.esperion.com,86400,8,3891 Ranchero Drive,Biotechnology,Suite 150
t-2,ESPR,-96190000.0,28192100,27954000.0,,-104476000,,-104476000,61555000,-34014000,-95569000,-95569000,,-8931000,,,,0,9638000,105207000,43652000,-8907000,,-104476000,-104476000,56000.0,797655000.0,449392000.0,-96134000.0,1662000.0,353258000.0,26000.0,-838817000.0,1290000.0,-54998000.0,304962000.0,94069000.0,5392000.0,7306000.0,345896000.0,,350579000.0,16136000.0,51975000.0,,34432000.0,170440000.0,-18326000.0,239000.0,89214000.0,-68550000.0,160000.0,-7075000.0,-9466000.0,-54799000.0,24994000.0,-12676000.0,280000000.0,-55000000.0,-176000.0,,251827000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,13.02,13.04,13.05,10,8,finmb_28236,NasdaqGM,"Esperion Therapeutics, Inc.",USD,573709,539883,0.21990013,0.017126178,12.84 - 40.2,-27.1401,-0.67512685,12.84,40.2,1620144060,1635764340,1636113600,-5.767,-5.23,-10.48,-1.2461737,-10.289,15.111667,-2.0517664,-0.13577367,22.679565,-9.619665,368186016,-2.4971128,-1.2693071,15,America/New_York,EDT,-14400000,False,False,NGM,0,REGULAR,-0.42415562,"Esperion Therapeutics, Inc.",13.0599,1630510370,0.039899826,13.16,13.21,12.885,98168,us_market,2,0.30645028,12.885 - 13.21,1.1,,,40.2,12.84,15.11,22.68,573.71k,539.88k,28.19M,,26.26M,1.58%,108.45%,9.02M,14.35,49.77%,34.33%,9.03M,,,,,,0.00%,,,1:6,"Jun 10, 2013","Dec 30, 2020","Jun 29, 2021",0.00%,-447.89%,-56.93%,,62.11M,2.32,-80.80%,78.22M,-277.55M,-324.52M,-5.77,,219.19M,7.75,514.6M,,3.33,-10.29,-292.16M,-215.61M,Value,48108,Healthcare,479,8,7,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",Ann Arbor,734 887 3903,MI,8,1609372800,1625097600,7,United States,http://www.esperion.com,86400,8,3891 Ranchero Drive,Biotechnology,Suite 150
t-3,ESPR,8960000.0,28192100,27954000.0,,-85437000,,-85437000,48826000,-31725000,-80551000,-80551000,,-4928000,,,,0,3833000,84384000,35558000,-4886000,,-85437000,-85437000,,743273000.0,242009000.0,8960000.0,1662000.0,250969000.0,28000.0,-734341000.0,1710000.0,,215748000.0,75947000.0,10926000.0,8110000.0,242803000.0,,160247000.0,9061000.0,17584000.0,56000.0,-11719000.0,1597000.0,-1053000.0,1643000.0,-82741000.0,-86671000.0,163000.0,-813000.0,-9466000.0,-46000.0,12188000.0,2333000.0,280000000.0,-55000000.0,83000.0,2250000.0,166856000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,13.02,13.04,13.05,10,8,finmb_28236,NasdaqGM,"Esperion Therapeutics, Inc.",USD,573709,539883,0.21990013,0.017126178,12.84 - 40.2,-27.1401,-0.67512685,12.84,40.2,1620144060,1635764340,1636113600,-5.767,-5.23,-10.48,-1.2461737,-10.289,15.111667,-2.0517664,-0.13577367,22.679565,-9.619665,368186016,-2.4971128,-1.2693071,15,America/New_York,EDT,-14400000,False,False,NGM,0,REGULAR,-0.42415562,"Esperion Therapeutics, Inc.",13.0599,1630510370,0.039899826,13.16,13.21,12.885,98168,us_market,2,0.30645028,12.885 - 13.21,1.1,,,40.2,12.84,15.11,22.68,573.71k,539.88k,28.19M,,26.26M,1.58%,108.45%,9.02M,14.35,49.77%,34.33%,9.03M,,,,,,0.00%,,,1:6,"Jun 10, 2013","Dec 30, 2020","Jun 29, 2021",0.00%,-447.89%,-56.93%,,62.11M,2.32,-80.80%,78.22M,-277.55M,-324.52M,-5.77,,219.19M,7.75,514.6M,,3.33,-10.29,-292.16M,-215.61M,Value,48108,Healthcare,479,8,7,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",Ann Arbor,734 887 3903,MI,8,1609372800,1625097600,7,United States,http://www.esperion.com,86400,8,3891 Ranchero Drive,Biotechnology,Suite 150
